Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
about
Environmental endocrine disruptors: Effects on the human male reproductive systemInhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival.Salmonella Bacterial Monotherapy Reduces Autochthonous Prostate Tumor Burden in the TRAMP Mouse ModelMiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer.Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy.Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2-8) in Normal and Cancerous Breast and Prostate Cells.Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells.Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.BH3 Mimetics for the Treatment of Prostate Cancer.Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential.TGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts.Treatment of metastatic prostate cancer after STAMPEDE.STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer.Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation.RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells.lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.Transcription Factor HBP1 Enhances Radiosensitivity by Inducing Apoptosis in Prostate Cancer Cell Lines.Identification of an IL-1-induced gene expression pattern in AR PCa cells that mimics the molecular phenotype of AR PCa cellsKLF4, a miR-32-5p targeted gene, promotes cisplatin-induced apoptosis by upregulating BIK expression in prostate cancer
P2860
Q28070418-A3F824EE-8515-4F20-B2FA-22192F9F1447Q33761619-3FC71468-F088-40AF-AA45-A54FC0F07444Q33780482-CF2FEAAE-A67B-4795-8844-9828FA79C3BAQ36098726-F0341635-482C-44E8-BA3D-086BC42BF45EQ37565167-56E4586F-9FF6-4305-BFCE-FF6EFEFE49A2Q37588088-050DDE90-2F03-4EF7-AB28-05AE23D36B35Q37588278-30B977A1-D00A-4992-A0E6-57B4CA79B5F8Q37631437-231BDC0B-B5B5-49B5-A7CA-CB274D846570Q38799227-28CDA122-EBCA-4E32-B431-4DB6A41311F8Q38896408-DF77C44A-8DBC-468A-AA65-3B1C14C5264DQ39193374-E81519D9-3F34-466E-A9FD-B5D97049214EQ39697612-F94C2E0B-9A63-4B38-9838-4D5DC636919AQ39997240-061C6B79-66AE-4CAE-AFBB-D40E62636D8FQ40970978-F9011F9D-59C2-44F1-A8D2-0A55999CF507Q41463153-F5363B61-A50E-4C6D-98C1-CA20249BFD5BQ42165985-6335E601-0251-4073-AB0D-69B2F7D74754Q42314595-8153B2C5-90DF-453D-AD18-D60908ADEE6EQ42353513-0FD6837A-7A27-482A-A547-4A37210CED64Q47110097-E31B56A0-2830-46DE-AFF3-D28E1D8E26A1Q47217714-5CD50227-AEFA-420C-8AC4-2DB6BD854355Q48182143-5F39C91C-0801-448C-83BA-413B227CEDC7Q52655185-AB9AA7C3-92FB-4FAD-B5CA-37A0950041B4Q52771926-A1E1BD96-2E6C-4307-81EA-91DFF46F171BQ53690759-4047FA8D-3CEF-4345-B21E-094A98369C62Q57822873-006F2DF9-9CF1-4EE2-A0EF-55515B89D9A0Q58768405-4C82C2CA-640F-4451-9C60-DD10B639728B
P2860
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@ast
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@en
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@nl
type
label
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@ast
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@en
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@nl
prefLabel
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@ast
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@en
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@nl
P3181
P1433
P1476
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
@en
P2093
Arndt Katzenwadel
P3181
P356
10.1016/J.CANLET.2015.06.021
P407
P50
P577
2015-10-10T00:00:00Z